The first experience with dabigatran antidote in the University Hospital Pilsen
Authors:
MUDr. Jitka Šlechtová; MUDr. Zdeňka Hajšmanová; MUDr. Alena Lavičková; MUDr. Pavla Šigutová
Authors‘ workplace:
Ústav klinické biochemie a hematologie LF UK a FN Plzeň
Published in:
Čas. Lék. čes. 2016; 155: 442-444
Category:
Case report
Overview
Dabigatran (Pradaxa, Boehringer Ingelheim) is the first direct oral thrombin (FIIa) inhibitor. It is indicated for thromboprophylaxis in patients undergoing elective total replacement hip or knee joint surgery or for the primary or secondary prophylaxis of elderly patients with non-valvular atrial fibrillation or for deep vein thrombosis and pulmonary embolism treatment and prophylaxis. Idarucizumab (Praxbind, Boehringer Ingelheim) is a specific monoclonal antibody fragment indicated in patients treated with dabigatran. It is recommended when reversal of anticoagulant effect of dabigatran is needed especially in cases of life-threatening bleeding, for emergency surgery or urgent procedures purposes. In this article, there is a summary of our clinical and laboratory experience with reversal effect of idarucizumab in our five patients.
Keywords:
dabigatran, idarucizumab, thrombin, diluted thrombin test
Sources
1. Van Ryn J et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant aktivity. J Thromb Haemost 2010; 103: 1116–1127.
2. Stangier J et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47–59.
3. Penka M, Michalcová J et al. Idarucizumab (Praxbind) – studie RE-VERSE AD. Hypertenze & kardiovaskulární prevence 2016; 5: 48–54.
4. Douxfils J, Mullier F, Robert S et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. J Thromb Haemost 2012; 107: 985–997.
5. Syed YY. Idarucizumab: a review as a reversal agent for dabigatran. Am J Cardiovasc Drugs 2016; 16: 297–304.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Avascular necrosis of the femoral head
- Femoroacetabular impingement − treatment options
- Rehabilitation after total knee and hip arthroplasty
- Limb shortening in the management of leg length discrepancy